ANIP Q4 2018 Earnings — ANI Pharmaceuticals, Inc. Revenue & Financial Results | Market Cap Arena

ANIPANI Pharmaceuticals, Inc.

$2B

Q4 2018 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$57M+20.8% YoY

Gross Profit

$37M64.8% margin

Operating Income

$11M20.0% margin

Net Income

$5M9.4% margin

EPS (Diluted)

$0.46

QoQ Revenue Growth

+12.7%

Cash Flow

Operating Cash Flow

$27M

Free Cash Flow

$26M

Stock-Based Comp.

$2M

Balance Sheet

Total Assets

$431M

Total Liabilities

$233M

Stockholders' Equity

$197M

Cash & Equivalents

$43M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$57M	$47M	+20.8%
Gross Profit	$37M	$27M	+37.8%
Operating Income	$11M	$7M	+55.1%
Net Income	$5M	-$10M	+155.8%

Revenue Segments

Sales Of Generic Pharmaceutical Products

$34M59%

Sales Of Branded Pharmaceutical Products

$19M33%

Sales Of Contract Manufactured Products

$4M6%

Product Development Services

$731,0001%

Other Revenues

$203,0000%

Geographic Segments

United States

$54M95%

Canada

$3M5%